Document is current
Any future updates will be listed below
-
Authors
Cohen, Yael C. https://orcid.org/0000-0002-9061-7287
Zada, Mor
Wang, Shuang-Yin https://orcid.org/0000-0001-9683-4103
Bornstein, Chamutal
David, Eyal
Moshe, Adi
Li, Baoguo
Shlomi-Loubaton, Shir
Gatt, Moshe E.
Gur, Chamutal
Lavi, Noa
Ganzel, Chezi https://orcid.org/0000-0002-1722-4807
Luttwak, Efrat https://orcid.org/0000-0003-0212-2135
Chubar, Evgeni
Rouvio, Ory
Vaxman, Iuliana https://orcid.org/0000-0002-8390-064X
Pasvolsky, Oren
Ballan, Mouna
Tadmor, Tamar
Nemets, Anatoly
Jarchowcky-Dolberg, Osnat
Shvetz, Olga
Laiba, Meirav
Shpilberg, Ofer
Dally, Najib
Avivi, Irit
Weiner, Assaf
Amit, Ido https://orcid.org/0000-0003-2968-877X
-
Funding
Funding for this research was provided by:
Amgen
European Molecular Biology Organization (ALTF 263‐2018)
- License Information
-
More Information
Article History
Received: 16 June 2020
Accepted: 7 January 2021
First Online: 22 February 2021
Competing interests
: The clinical trial was an investigator-initiated study (IIS); as such, Y.C. acted as sponsor for the study. The IIS was approved by Amgen, who provided funding and supply of the clinical drug CFZ. Y.C. is a consultant for Janssen, Amgen, Neopharm, Takeda and Madison. A patent application has been filed related to this work. The other authors declare no competing interests.
